Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01083641 · ClinicalTrials.gov registry record · Phase 2
Estrogen for Triple Negative Breast Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01083641 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 17 participants.
The verdict
NCT01083641, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of Estradiol treatment for advanced breast cancer that is hormone receptor negative and Her2/neu negative. The study will also use tumor tissue from your original diagnosis or from a biopsy you may have had for your cancer to look at hormone receptors in the lab. The tissue left over from your previous surgery or a previous biopsy will be used for research tests to check whether a different estrogen receptor (estrogen receptor beta) is seen in the tumor and if that makes estrogen work better.
Interventions
- DRUG Estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01083641
The ClinicalTrials.gov registry entry for NCT01083641 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Estradiol is the first listed.
NCT01083641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01083641 about?
NCT01083641 is a clinical study titled "Estrogen for Triple Negative Breast Cancer". The purpose of this study is to determine the effectiveness of Estradiol treatment for advanced breast cancer that is hormone receptor negative and Her2/neu negative. The study will also use tumor tissue from your original diagnosis or from a biopsy you may have had for your cancer to look at hormon...
What is the current status of trial NCT01083641?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2010-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01083641?
The interventions under investigation include: Estradiol (DRUG).
Who is sponsoring clinical trial NCT01083641?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.